AATI Featured in CRISPR Commentary
Published: Tuesday, October 3rd, 2017
AATI’s own Steve Siembieda, Vice President of Commercialization, recently penned a commentary in DDNews on two primary issues in CRISPR genome editing: (1) low specificity and (2) low efficiency. Put simply, CRISPR technology produces too many off-target mutations and does not have the success rate necessary for adoption into sensitive applications, notably the treatment of genetic illnesses. The article went on to discuss potential remedies for low specificity and low efficiency in CRISPR workflows and the associated QC and mutation screening challenges. The Fragment Analyzer supports these remedies and fulfills the QC and screening needs of CRISPR pipelines, accurately assessing the suitability of reagents and identifying and characterizing positive lines.
Learn more about how AATI can improve your CRISPR workflow.
- AATI’s Mutation Screening Method for CRISPR Workflows Featured in GEN
- AATI Publishes CRISPR Mutation Screening Protocol
- Advanced Analytical Technologies, Inc. (AATI) is Part of Rewriting CRISPR Workflow
- AATI presented at Genome Engineering: The CRISPR-Cas Revolution
- Genome Editing & Gene Modulation International Congress takes place in Oxford